Impact of Angiotensin II Receptor Blocker Therapy (Olmesartan or Valsartan) on Coronary Atherosclerotic Plaque Volume Measured by Intravascular Ultrasound in Patients With Stable Angina Pectoris - 18/07/13
, Masakazu Kobayashi, MD, PhD a, Nobutake Kurebayashi, MD a, Daiji Yoshikawa, MD a, Susumu Suzuki, MD a, Satoshi Ichimiya, MD, PhD b, Masaaki Kanashiro, MD, PhD b, Takahito Sone, MD, PhD c, Hideyuki Tsuboi, MD, PhD c, Tetsuya Amano, MD, PhD a, Tadayuki Uetani, MD, PhD d, Ken Harada, MD, PhD a, Nobuyuki Marui, MD, PhD d, Toyoaki Murohara, MD, PhD aAbstract |
Coronary plaques can be reduced by some medications. The aim of this study was to compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or valsartan at 80 mg/day) on coronary plaque by coronary intravascular ultrasound. One hundred hypertensive patients with stable angina pectoris who underwent elective percutaneous coronary intervention were randomly selected to receive 1 of the 2 angiotensin II receptor blockers after coronary intervention. Nontarget coronary lesions with mild to moderate stenosis were measured by volumetric intravascular ultrasound at baseline and after 6 months. After 6 months, both the olmesartan and the valsartan groups showed significant reduction of the examined coronary plaque volume (46.2 ± 24.1 mm3 at baseline vs 41.6 ± 21.1 mm3 at 6 months: 4.7% decrease, p = 0.0002; and 47.2 ± 32.7 mm3 at baseline vs 42.5 ± 30.2 mm3 at 6 months: 4.8% decrease, p = 0.002, respectively). There was no statistically significant difference of plaque regression between the 2 groups (p = 0.96). In conclusion, there was a significant decrease from baseline in the coronary plaque volume in patients with stable angina pectoris who received olmesartan or valsartan for 6 months. In addition, there was no significant difference in the reduction of plaque volume achieved by these 2 medications.
Le texte complet de cet article est disponible en PDF.Plan
| See page 367 for disclosure information. |
Vol 112 - N° 3
P. 363-368 - août 2013 Retour au numéro
Article précédent
- Cost-Effectiveness of Universal and Platelet Reactivity Assay-Driven Antiplatelet Therapy in Acute Coronary Syndrome
- Craig I. Coleman, Brendan L. Limone
- Comparison of Lipid Deposition at Coronary Bifurcations Versus at Nonbifurcation Portions of Coronary Arteries as Determined by Near-Infrared Spectroscopy
- Jacob C. Townsend, Daniel H. Steinberg, Christopher D. Nielsen, Thomas M. Todoran, Chetan P. Patel, Robert A. Leonardi, Bethany J. Wolf, Emmanouil S. Brilakis, Kendrick A. Shunk, James A. Goldstein, Morton J. Kern, Eric R. Powers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?